Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
52,953 Cancer
clinical trials

Oncology Clinical Trial
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Accumed Research Associates
mi
from
Garden City, NY
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry
Status: Enrolling, Phase
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Colorectal Cancer Clinical Trial
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Status: Enrolling, Phase I, II
Updated: 12/1/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hepatocellular Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Status: Enrolling, Phase II
Updated: 12/31/1969
Baylor Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Hepatocellular Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Status: Enrolling, Phase II
Updated: 12/31/1969
Gundersen Health System
mi
from
La Crosse, WI
Click here to add this to my saved trials
Hepatocellular Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Status: Enrolling, Phase II
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hepatocellular Carcinoma Clinical Trial
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
Status: Enrolling, Phase II
Updated: 12/31/1969
UPMC Cancer Center - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
Moffitt Cancer Center International Plaza
mi
from
Tampa, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Enrolling, Phase II
Updated: 12/31/1969
Smilow Cancer Hospital-Waterbury Care Center
mi
from
Waterbury, CT
Click here to add this to my saved trials
Pancreatic Cancer Clinical Trial
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
Status: Enrolling, Phase II
Updated: 4/23/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Medical City Dallas Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Carle on Vermilion
mi
from
Danville, IL
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente - Moanalua Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Nemours Children's Clinic - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Summerlin Hospital Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Valley Children's Hospital
mi
from
Madera, CA
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Carle Physician Group-Mattoon/Charleston
mi
from
Mattoon, IL
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Steven & Alexandra Cohen Children's Medical Center of New York
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Beaumont Children's Hospital-Royal Oak
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas Medical Branch at Galveston
mi
from
Galveston, TX
Click here to add this to my saved trials
Prostate Cancer Clinical Trial
Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Kansas City VA Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Prostate Cancer Clinical Trial
Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Associated Medical Professionals of NY
mi
from
Syracuse, NY
Click here to add this to my saved trials
Prostate Cancer Clinical Trial
Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Texas Urology Specialists
mi
from
Tomball, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Status: Enrolling, Phase II
Updated: 12/31/1969
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Status: Enrolling, Phase II
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Status: Enrolling, Phase II
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Malignancies Clinical Trial
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Status: Enrolling, Phase I
Updated: 12/31/1969
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Malignancies Clinical Trial
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Status: Enrolling, Phase I
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Malignancies Clinical Trial
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Status: Enrolling, Phase I
Updated: 12/31/1969
Henry Ford Health Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Malignancies Clinical Trial
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Status: Enrolling, Phase I
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Malignancies Clinical Trial
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Status: Enrolling, Phase I
Updated: 12/31/1969
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Oncology Clinical Trial
Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Oncology Clinical Trial
Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
Status: Enrolling, Phase I
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Status: Enrolling, Phase III
Updated: 12/31/1969
Lehigh Valley Hospital - Muhlenberg
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Alaska Urological Institute DBA Alaska Clinical Research Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Local Institution
mi
from
Birmingham, AL
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Hattiesburg Clinic
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Local Institution
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Ochsner Clinic
mi
from
New Orleans, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Doctors Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Colorado Cancer Research Program
mi
from
Denver, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
St. Elizabeth Healthcare Edgewood
mi
from
Edgewood, KY
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Cape Fear Valley Health System
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Southeastern Medical Oncology Center
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Carolina East Medical Center
mi
from
New Bern, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
Status: Enrolling
Updated: 12/31/1969
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
Status: Enrolling, Phase II
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Prostate Cancer Clinical Trial
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Status: Enrolling, Phase I
Updated: 4/19/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Status: Enrolling, Phase I
Updated: 2/9/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Status: Enrolling, Phase II
Updated: 3/29/2018
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Cancer Clinical Trial
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Cancer Clinical Trial
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Sarah Cannon Research Institute at HealthONE
mi
from
Denver, CO
Click here to add this to my saved trials
Cancer Clinical Trial
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Cancer Clinical Trial
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Endocrinology, Oncology Clinical Trial
Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Uc Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Ironwood Cancer and Research Centers
mi
from
Chandler, AZ
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
USC Norris Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Urology Cancer Center & GU Research Network
mi
from
Omaha, NE
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Allegheny Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Metastatic Prostate Cancer Clinical Trial
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling, Phase III
Updated: 12/31/1969
Associates in Oncology and Hematology
mi
from
Rockville, MD
Click here to add this to my saved trials